Get the Stockscreener App
101.33
1.76%
-1.82
Pre-market:
102.93
1.60
+1.58%
Nuvalent Inc stock is traded at $101.33, with a volume of 365.48K.
It is down -1.76% in the last 24 hours and up +2.19% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$103.15
Open:
$104.53
24h Volume:
365.48K
Relative Volume:
0.61
Market Cap:
$7.87B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-25.98
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+0.43%
1M Performance:
+2.19%
6M Performance:
+32.27%
1Y Performance:
+24.73%
1-Day Range:
$100.63
$106.57
1-Week Range:
$98.65
$106.57
52-Week Range:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
101.33 | 8.01B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
NUVL: Global launches of innovative ROS1 and ALK inhibitors drive growth and pipeline expansion - TradingView
Nuvalent honors women pioneers on Women in Science Day - Traders Union
Candriam S.C.A. Purchases 28,462 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Assessing Nuvalent (NUVL) Valuation As DCF Signals Upside Versus Current Market Pricing - Yahoo Finance
US Stocks Recap: Is Nuvalent Inc forming a bullish divergenceJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Morningstar
Liquidity Mapping Around (NUVL) Price Events - Stock Traders Daily
Nuvalent, Inc. (NUVL) Investor Outlook: Biotechnology Innovator with a 37.73% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NUVL): Investor Outlook With A 33% Potential Upside - DirectorsTalk Interviews
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Final Week: Is Nuvalent Inc benefiting from innovation trendsBreakout Watch & Long-Term Growth Plans - baoquankhu1.vn
Why (NUVL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 14,300 Shares of Stock - MarketBeat
Deborah Ann Miller Sells 700 Shares of Nuvalent (NASDAQ:NUVL) Stock - MarketBeat
Nuvalent Inc stock hits 52-week high at 112.89 USD By Investing.com - Investing.com Australia
Nuvalent (NASDAQ:NUVL) Reaches New 52-Week HighHere's Why - MarketBeat
Nuvalent Inc stock hits 52-week high at 112.89 USD - Investing.com
Market Trends: What analysts say about OSUR stockJuly 2025 Technicals & Fast Entry and Exit Trade Plans - baoquankhu1.vn
SG Americas Securities LLC Takes Position in Nuvalent, Inc. $NUVL - MarketBeat
Jefferies Keeps Their Buy Rating on Nuvalent (NUVL) - The Globe and Mail
Nuvalent (NASDAQ:NUVL) Stock Price Up 7.3%Here's Why - MarketBeat
Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans - TechStock²
FDA accepts Nuvalent’s NDA for ROS1-positive NSCLC treatment By Investing.com - Investing.com Nigeria
Understanding Momentum Shifts in (NUVL) - Stock Traders Daily
Nuvalent (NASDAQ:NUVL) Stock Price Down 6.7%What's Next? - MarketBeat
Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones - Investing News Network
Downgrade Watch: How buybacks impact Nuvalent Inc stock valueJuly 2025 Action & High Accuracy Buy Signal Tips - Bộ Nội Vụ
This Insider Has Just Sold Shares In Nuvalent - simplywall.st
Aug Intraday: Will Nuvalent Inc. stock outperform growth indexesJuly 2025 Chart Watch & Fast Entry High Yield Tips - Улправда
Will Nuvalent Inc. stock outperform tech sector in 2025Trend Reversal & Capital Efficient Trade Techniques - Улправда
How Nuvalent Inc. stock performs in weak economy2025 AllTime Highs & Low Risk Entry Point Guides - Улправда
Will Nuvalent Inc. stock return to pre crisis levelsJuly 2025 Snapshot & Real-Time Volume Trigger Notifications - Улправда
How buybacks impact Nuvalent Inc. stock valueRate Hike & Community Trade Idea Sharing Platform - Улправда
Is Nuvalent Inc. stock in correction or buying zone2025 Short Interest & AI Based Buy and Sell Signals - Улправда
Is Nuvalent Inc. stock a defensive play in 2025Dividend Hike & Daily Growth Stock Investment Tips - Улправда
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com - Investing.com India
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com - Investing.com South Africa
Will Nuvalent’s Momentum Continue? - StocksToTrade
Nuvalent (NASDAQ:NUVL) Insider Sells $251,547.24 in Stock - MarketBeat
Nuvalent (NASDAQ:NUVL) CFO Sells $309,065.96 in Stock - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 2,496 Shares of Stock - MarketBeat
Nuvalent (NASDAQ:NUVL) Insider Sells $412,247.52 in Stock - MarketBeat
Nuvalent (NASDAQ:NUVL) Insider Sells $309,065.96 in Stock - MarketBeat
Nuvalent CSO Pelish sells shares worth $501,752 - Investing.com India
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock By Investing.com - Investing.com South Africa
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock - Investing.com Australia
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):